Publications Metastatic Breast Cancer

  • Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

    Istvan Lang, Thomas Brodowicz, Larisa Ryvo, Zsuzsanna Kahan, Richard Greil, Semir Beslija, Salomon M Stemmer, Bella Kaufman, Zanete Zvirbule, Günther G Steger, Bohuslav Melichar, Tadeusz Pienkowski, Daniela Sirbu, Diethelm Messinger, Christoph Zielinski

    Lancet Oncol 2013; 14:125-33

    The Lancet Oncology, Early Online Publication, 10 January 2013 doi:10.1016/S1470-2045(12)70566-1

  • Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.

    I.Lang, M.J. Inbar, Z. Kahan, R. Greil, S. Beslija, S. M. Stemmer, B. Kaufman, Z. Zvirbule, G. G. Steger, D. Messinger, T. Brodowicz, C. Zielinski

    Eur J Cancer (2012)

  • Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG).

    A. Tomova, R. Bartsch, T. Brodowicz, V. Tzekova , C. Timcheva, C. Wiltschke, DA Gerges , J. Pawlega, S. Spanik, M. Inbar, CC Zielinski.

    Breast Cancer Res. Treat Jan. 2010, 119(1) 169-76

  • Concomitant Docetaxel plus Gemcitabine (DG) vs. Sequential Docetaxel followed by Gemcitabine (D->) in Anthracycline-Pretreated Metastatic or Locally Recurrent Breast Cancer Patients: A Multicenter Phase III Trial of the Central European Cooperative Oncology Group (CECOG).

    A. Tomova, T. Brodowicz, V. Tzekova, C. Timcheva, C. Wiltschke, D. Abi Gerges, J. Pawlega, S. Spanik, M. Inbar, C. Zielinski

    J. Clin. Oncol (Supplement to 26) 2008: # 1106

  • Gemcitabine/Epirubicin/Paclitaxel versus 5-Fluorouracil/Epirubicin/Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial.

    C. Zielinski, S. Beslija, Z. Mrsic-Krmpotic, M. Welnicka-Jaskiewicz, C. Wiltschke, Z. Kahan, M. Grgic, V. Tzekova, M. Inbar, J. Cervek, I. Chernozemsky, J. Szanto, S. Spanik, M. Wagnerova, N. Ghilezan, J. Pawlega, D. Vrbanec, D. Khamtsov, V. Soldatenkova, T. Brodowicz.

    JCO Mar 1, 2005:1401-1408; DOI:10.1200/JCO.2005.12.106.

  • Capecitabine vs. capecitabine + trastuzumab in patients with HER-2 positive metastatic breast cancer progressing during trastuzumab treatment – the TBP phase III study (GBG 26/BIG3-05).

    von Minckwitz, C. Zielinski, E. Maarteense, P. Vogel, M. Schmidt, H. Eidtmann, T. Cufer, F. E. de Jongh, M. Kaufmann, S. Loibl

    J. Clin. Oncol. 26:2008 (May 20 suppl; abstr. 1025).

  • Consensus on Medical Treatment of Metastatic Breast Cancer

    Semir Beslija, Jacques Bonneterre, Harold J. Burstein, Michael Gnant, Pamela Goodwin, Volker Heinemann, Jacek Jassem, Wolfgang Köstler, Michael Krainer , Silvie Menard, David Miles, Lubos Petruzelka, Kurt Possinger, Peter Schmid, Edward Stadtmauer, Martin Stockler, Simon Van Belle, Charles Vogel, Nicholas, Wilcken, Christoph Wiltschke, Christoph Zielinski, Heinz Zwierzina

    Breast Cancer Res. Treatment; 81 Suppl. 1, 1-7, 2003

    Second Consensus on Medical Treatment of Metastatic Breast Cancer

    Ann Oncol. 2007 Feb; 18(2): 215-25. Epub 2006 Jul 10. Review.

    Third Consensus on Medical Treatment of Metastatic Breast Cancer

    Ann Oncol. 2009 Nov; 20(11):1771-85. Epub 2009 Jul 16. Review.